Description: Podoplanin is a 40-kDa type I transmembrane sialomucin-like glycoprotein involved in platelet aggregation and cancer metastasis. This protein is expressed on lymphatic endothelial cells and follicular dendritic cells, as well as on many human cancers, including squamous cell carcinoma, glioblastoma, seminoma, and mesothelioma. Podoplanin expression has been demonstrated to be regulated by the Fos protein of the Activating Protein-1 (AP-1) transcription factor complex. Much of its functionality arises via interaction with its endogenous receptor, C-type lectin-like receptor-2 (CLEC-2).
This antibody has been reported to block the interaction between Podoplanin and CLEC-2.
Applications Reported: This NZ-1.3 antibody has been reported for use in immunoprecipitation, immunoblotting (WB), and immunohistology staining of paraffin embedded tissue sections.
Applications Tested: This NZ-1.3 antibody has been tested by immunoblot analysis of U87 cells. This can be used at 1-5 µg per mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Podoplanin (PDPN, T1A, gp38, Aggrus) is a mucin type-1 glycoprotein with a 40-43 kDa molecular weight. Podoplanin is expressed in many tumors and normal cells, especially lymphatic epithelial cells and follicular DCs. Podoplanin localizes in stromal cells of peripheral lymphoid tissue and thymic epithelial cells. As a regulator of the lymphatic endothelium, podoplanin probably plays a role in maintaining the unique shape of podocytes. Podoplanin appears to serve as a ligand for CLEC-2 and expression is positively correlated with tumors expressing greater invasive and metastatic potential. Podoplanin is directly involved in cell migration, aids metastases formation and tumor cell invasion of tissue. Further, it has also been determined that podoplanin expression is induced through Src activation of Cas and, recently, there are indications of podoplanin presence on Th17 cells. Initial studies below indicate the presence of podoplanin on a small but distinct population of CD4+ cells from human PBMC. Dysfunction of the podoplanin protein has been linked to diseases such as lymphangioma and subglottis neoplasm. Podoplanin has also been proposed as a marker for lung injury due to the physiological function of the protein.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 29kDa cytosolic podoplanin intracellular domain; Aggrus; CTA-520D8.1; E11; E11 antigen epitope; epithelial cell surface transmembrane protein antigen; Glycoprotein 36; Glycoprotein 38; glycoprotein, 36-KD; Gp36; Gp38; hT1alpha-1; hT1alpha-2; lung type I cell membrane associated glycoprotein; lung type-I cell membrane-associated glycoprotein (T1A-2); OTS-8; OTTHUMP00000009640; OTTHUMP00000044504; PA2.26 antigen; PDPN; PICD; Podoplanin; pulmonary type I alveolar epithelial cell transmembrane differentiation marker; RP23-348F1.2; RTI140; T1-alpha; T1A; Transmembrane glycoprotein E11; Type I cell 40 kDa protein
Gene Aliases: AGGRUS; E11; GP36; Gp38; GP40; HT1A-1; OTS-8; OTS8; PA2.26; PDPN; PSEC0003; PSEC0025; RANDAM-2; RTI40; T1-alpha; T1A; T1A-2; T1A2; T1alpha; TI1A